Objectives: Recent studies have shown that lymphoid enhancer binding factor 1 (LEF1) is a useful marker for chronic lymphocytic B-cell leukemia (CLL)/small lymphocytic lymphoma. Yet, it is not still being widely used in a diagnostic setting. In this study, we document the experience with LEF1 immunohistochemistry during routine diagnostics.
Results: LEF1 expression was strong and diffuse (>70% of cells) in most cases. Few CLL cases showed a staining in proliferation centers only. Seventy-seven of 80 CLL cases expressed LEF1. Other entities expressing LEF1 included one of 38 follicular lymphomas, two of 33 marginal zone lymphomas, and one diffuse large B-cell lymphoma with a background of follicular lymphoma grade 3B. Sensitivity for LEF1 for the diagnosis of CLL was 0.96, and specificity was 0.93.
Conclusions:
In this study, we could demonstrate the diagnostic utility of LEF1. LEF1 is a sensitive and specific marker for CLL and is helpful in the diagnosis of diagnostically challenging small B-cell lymphomas.
Lymphoid enhancer binding factor (LEF1) is an important transcription factor for B cells and T cells and a crucial mediator of the wingless-type mouse mammary tumor virus integration site (Wnt)/b-catenin pathway. 1 By forming a nuclear complex with the T-cell factor and b-catenin, transcription of various genes related to cell survival and proliferation is initiated. 2 Klein et al 3 were the first to show upregulation of LEF1 in chronic lymphocytic B-cell leukemia (CLL)/small lymphocytic lymphoma by gene expression analysis. It has also been shown that the Wnt pathway is constitutively activated in CLL as well in its precursor form, monoclonal B-cell lymphocytosis. 4 CLL is the most common form of leukemia in the Western world, 5 and thus it is often a differential diagnosis when pathologists deal with small cell mature lymphoid infiltrates in the bone marrow, lymph nodes, and other organs. Despite having wellestablished morphologic and immunophenotypic characteristics, 5 Upon completion of this activity you will be able to:
• describe the biological role of LEF1 in hematopoietic tissues.
• define the application of LEF1 immunohistochemistry in the routine workup of B-cell lymphomas.
• compare and explain the staining performance of antibodies recognizing LEF1 related to the different variables during the staining process.
The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit TM per article. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module.
The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.
Exam is located at www.ascp.org/ajcpcme.
diagnosis in a proportion of small B-cell lymphomas is challenging, and immunohistochemical markers would be helpful to confirm or reject a diagnosis of CLL. On the basis of the findings alluded to above, few studies have investigated the usefulness and the applicability of LEF1 immunohistochemistry in CLL both on whole sections 6, 7 as well as on tissue microarrays (TMAs). 8, 9 These studies have confirmed the usefulness of LEF1 in the diagnosis of CLL, as most other small B-cell lymphomas do not express LEF1. Amador-Ortiz et al 10 have demonstrated the value of LEF1 in multiparameter flow cytometry diagnosis of CLL. Other hematolymphoid malignancies that consistently express LEF1 include Burkitt lymphoma, 8 certain subsets of T-cell lymphomas, 6 and acute lymphoblastic leukemias/lymphomas of T-and B-cell lineage. 6, 11 Recently, several epithelial tumors have been reported to express LEF1, 12, 13 and some studies also describe LEF1 as an independent prognostic factor in colorectal carcinoma. 14, 15 In this retrospective study, we present and discuss the results of LEF1 immunohistochemistry applied during routine diagnostic workup of small B-cell lymphomas in a diagnostic and referral center for hematopathology.
Materials and Methods

Case Selection
All cases in which LEF1 immunohistochemistry was performed for diagnostic purposes at the Department of Cellular Pathology, Hammersmith Campus, Imperial College NHS Healthcare Trust (London, UK) were retrieved from our pathology database. Table 1 lists all entities/diagnoses and the respective expression of LEF1. Investigation of LEF1 for diagnostic purposes was initiated at Hammersmith in August 2015. Altogether, the Hammersmith cohort consisted of 191 specimens from 181 patients. All reports were evaluated for the final diagnosis and the expression of LEF1. If available, biopsy results were correlated with multiparameter flow cytometry (MFC) results. In unusual cases, the slides were retrieved from the archives and reviewed to confirm the initial diagnosis.
Lymph node (LN) biopsy specimens were fixed in 10% buffered formalin for not more than 24 hours before further processing. Bone marrow trephine biopsy (BMTB) specimens were fixed and processed as per the Hammersmith Hospital bone marrow trephine processing protocol. 16 Briefly, this involved fixation in acetic acid-zinc-formalin fixative, short decalcification with 10% formic acid/5% formaldehyde solution, and paraffin wax embedding.
Staining for LEF1
The monoclonal antibody for LEF1 clone EPR2029Y (Abcam, Cambridge, UK) was used. Slides were processed on the Leica Bond system (Leica Biosystems, Wetzlar, Germany), and the dilution of the primary antibody was 1:100. For antigen retrieval, heat-induced epitope retrieval using the citrate-based pH 6.0 ER1 solution (Leica Biosystems) was used for 30 minutes. Incubation time of the primary antibody was 20 minutes. Detection with 3,3 0 -diaminobenzidine was used.
Data Analysis
Data were collected and analyzed using Microsoft Excel 2010 (Microsoft, Redmond, WA). Statistical analysis was performed using SPSS version 22 (SPSS, Chicago, IL).
Results
General Evaluation of the LEF1 Immunohistochemical Staining
Only nuclear staining of LEF1 was regarded as "positive." LEF1 staining showed an easily identifiable nuclear staining with negligible background staining Image 1A and Image 1B . Positive reactive T cells were used as internal controls. LEF1 staining was strong and diffuse in most of the "positive" cases, and a threshold of 70% was used to score a case as positive in the few cases that did not show a completely homogeneous staining or a pattern predominantly highlighting proliferation centers. This percentage was estimated; a detailed cell count was not performed. If LEF1 was only strongly expressed in proliferation centers of CLL cases, this was also counted as positive, and the pattern of staining was documented in the report. Negative cases showed strong nuclear staining in the reactive T-cell population only. No difference was seen in staining intensity or staining pattern between decalcified BMTB and LN specimens.
Expression of LEF1 in CLL Cases
Seventy-seven (96%) of 80 CLL cases expressed LEF1 (Image 1A, B). Biopsy sites included BMTB (n ¼ 41), LN (n ¼ 30), and others (n ¼ 9). The classic morphology of small lymphoid cells with scanty cytoplasm and clumped chromatin, as well as the presence of proliferation centers, was seen in 69 of 77 LEF1þ cases and two of three LEF1-cases. In two cases, LEF1 was expressed only in proliferation centers but not in the diffuse areas. One additional CLL case with the presence of high-grade transformation (Richter transformation) showed a preserved expression of LEF1 in the smaller lymphocytes, which also showed classic CLL morphology, while the large atypical cells were negative for LEF1. All but two CLL cases showed the classic immunophenotype CD20þ/CD5þ/CD23þ/CD10-/ cyclin D1-(some cases showed occasional cyclin D1þ cells within the proliferation centers). The other two CLL cases were negative for CD23. MFC data were available for 24 CLL cases. Three of these showed atypical cytologic features in the aspirate; in two of the three cases, atypical cytologic features were also appreciated on BMTB specimens. One case showed a weak/negative expression of CD5 in MFC while being unequivocally positive in the BMTB specimen. All cases had a CLL score of 4 to 5/5. One case had been reported as B-cell lymphoma on both the LN needle core biopsy and the BMTB specimens and not as CLL since the cells were LEF1-. However, the whole LN biopsy specimen, which had the classic immunohistochemical profile of CLL, showed LEF1 expression restricted to the proliferation centers (a finding we had already observed in our previous study 9 ), which might explain the LEF1 negativity in the core needle biopsy specimen.
Beside the above case, two other CLL biopsy specimens were negative for LEF1. The first case was a BMTB specimen with an infiltrate of 20% of B cells with the classic CLL morphology and the classic immunophenotype CD20þ/ CD5þ/CD23þ. No MFC data or further follow-up were available for this external referral case. The second case was an LN biopsy specimen showing a diffuse infiltrate of atypical small lymphoid cells with characteristic morphologic features of CLL with the presence of proliferation centers. The diffuse infiltrate was CD20þ/CD5þ/CD23þ/BCL2þ/ BCL6-/CD10-/cyclin D1-. MUM1 was weakly expressed in proliferation centers. Similar to the former case, this was also an external referral case, so no further follow-up or results on bone marrow investigations were available.
No statistically significant difference of LEF1 positivity was observed between BMTB, LN, or other tissue samples.
LEF1 Expression in Other Entities
LEF1 was expressed in one of 38 follicular lymphomas (FLs) of the Hammersmith cohort. LEF1 expression was diffuse and strong Image 2 . This case of FL grade 2 showed cells with pale cytoplasm, suggesting a marginal zone differentiation, and the immunophenotype was CD20þ/CD5þ/BCL2þ/BCL6þ/CD10þ/IgMþ/LEF1þ/ MUM1-/CD21-/CD23-/IgD-/cyclin D1-.
One case of diffuse large B-cell lymphoma with a background of FL grade 3B showed patchy expression of LEF1 in the large atypical cells (see Image 2) . The immunophenotype of this lymphoma was CD20þ/CD10þ/CD21þ/ CD23þ/BCL2þ/BCL6þ/LEF1þ/CD5-/cyclin D1-.
Two of 33 marginal zone lymphomas (MZLs) showed expression of LEF1, and one of the two was CD5þ. Both cases were LN needle core biopsy specimens. The diagnosis of CLL was excluded based on morphology of the lymphoid cells that was typical for MZL, lack of proliferation centers, and the immunophenotype. Both cases also showed colonized follicles that were highlighted on CD21 and CD23 immunostains. The CD5þ case was negative for CD23, CD10, and BCL6. The CD5-case expressed CD23 and MUM1 (see also Image 2) .
Two cases of B-cell acute lymphoblastic leukemia in the BMTB specimen and one case of T-cell acute lymphoblastic leukemia/lymphoma involving the LN were stained for LEF1 and showed a strong homogeneous expression.
None of the cases of mantle cell lymphoma (n ¼ 10) or lymphoplasmacytic lymphoma (n ¼ 12) expressed LEF1.
LEF1 Expression in Cases of "Small B-Cell Lymphomas, Not Further Subclassifiable"
Five of 136 specimens in our cohort were reported as small B-cell lymphoma and could not be further classified. Four of these showed no evidence of LEF1 expression. Biopsy specimens were small, and some were technically suboptimal. Matutes score was less than 4 of 5 in these cases on MFC. One case that was LEF1þ was reported as B-cell lymphoma with follicular center phenotype and relatively high proliferation. It showed a diffuse infiltrate of small-to medium-sized lymphoid cells with scanty to moderate amounts of pale cytoplasm, fine chromatin, and inconspicuous nucleoli. The immunophenotype of this lymphoma was CD20þ/PAX5þ/CD10þ/BCL2þ/BCL6þ/LEF1þ/CD5-/ CD34-/TdT-/CD21-/CD23-/c-MYC-/cyclin D1-/MUM1-. The proliferation rate shown by Ki-67 expression was 50%. The case lacked a follicular pattern, and centroblasts could not be discerned. Hence, a definitive diagnosis of FL could not be made. Furthermore, fluorescence in situ hybridization analysis for BCL2 or BCL6 translocation could not be attempted as tissue from this needle core biopsy specimen was depleted following immunohistochemistry.
Specificity and Sensitivity of LEF1 Expression for Diagnosis of CLL in the Setting of a Small B-Cell Lymphoma
Sensitivity and specificity were calculated including only cases with a definite diagnosis. Sensitivity for the diagnosis of CLL was 0.96; specificity for LEF1 for the diagnosis of CLL was 0.93. lymphoma cells (F, x200) .
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Image 2 (cont) G-L, Nodal marginal zone lymphoma. Overview shows remnants of a follicle in the center that is colonized by lymphoma cells (G, H&E, x200) . H, Cytologic features of marginal zone lymphoma (x400). Lymphoma cells express CD20 (I, x200), CD23 (which also shows remnant FDC meshworks) (J, x200), and LEF1 (K, x200) but are negative for CD5, which only stains small T cells (L, x200).
solution in an ultrasonic device at 18 C for 12 to 24 hours.
Altogether, that cohort contained 55 specimens from 50 patients. The staining pattern was more heterogeneous in this cohort (see also Image 1C and Image 1D); LEF1 staining was restricted to CLL cases only. Values for sensitivity and specificity were 0.70 and 1.0, respectively, as 30% of CLL cases did not express LEF1. As in the Hammersmith cohort, the staining pattern and intensity did not differ between decalcified and nondecalcified specimens.
Discussion
In this retrospective study on lymphomas that were investigated during routine diagnosis, we evaluated the usefulness and applicability of LEF1 immunohistochemistry in a large center for hematopathology. LEF1 proved to be a reliable marker for CLL, with its expression being found in only very few cases of other B-cell lymphomas. This further underscores the usefulness of LEF1 as a confirmatory marker for CLL, on one hand, and in the differential diagnosis of small B-cell lymphomas, on the other.
In concordance with previous literature, [7] [8] [9] we showed that LEF1 expression is mainly restricted to CLL among small B-cell lymphomas. However, since LEF1 is constitutively expressed in a subset of T cells, 17 LEF1 expression might be difficult to evaluate in cases that have a prominent reactive infiltrate of T cells and fewer neoplastic B cells.
Together with other markers, CD20, CD23, and CD5, it can be a helpful tool to detect low-volume residual disease (especially if one adopts double staining of CD20 and LEF1) or to document concomitant infiltrations of two different lymphomas in one biopsy specimen (one of them being CLL). In most LEF1þ cases, LEF1 expression was seen as uniformly diffuse nuclear staining in the Hammersmith cohort using the Leica immunostainer. A cutoff of 70% was used to identify negative cases with a heavy infiltrate of T cells (including rare cases in which reactive T cells exceed non-CLL B-cell lymphoma cells). It has been previously described by several authors that LEF1 expression can be stronger in proliferation centers, 7,9 and we could confirm this finding in our unselected cohort of CLL cases. Proliferation centers are known to have the highest activity of various signaling pathways. 18, 19 It is hence likely that LEF1, which acts downstream of Wnt signaling, is more prominently expressed in proliferation centers in some cases of CLL. Among the LEF1þ non-CLL cases, one case of MZL and one case of FL showed aberrant expression of CD5. Most FLs are CD5-and only a minority of MZLs are CD5þ. CLL had been ruled out in these two instances based on morphologic as well as immunophenotypic assessment. The MZL case showed both lack of proliferation centers as well as CD23 expression. Furthermore, CD21 showed colonization of follicles, a hallmark of MZL. The FL case showed expression of CD10, and morphology suggested a marginal zone differentiation (see also Image 2D-I). As in the MZL case, the classic cytologic features of CLL were not seen, and there were no proliferation centers. It would be interesting to further evaluate LEF1 expression in CD5þ FL and MZL: does aberrant expression of CD5 go hand-in-hand with aberrant expression of LEF1 in these two entities?
When comparing the findings of the Hammersmith cohort with an unselected cohort of routine cases of small Bcell lymphomas from another referral center for hematopathology, a difference in LEF1 staining patterns was observed, although the same monoclonal antibody had been applied. This resulted in a lower sensitivity of 0.70 in the Basel cohort in comparison to 0.96 in the Hammersmith cohort. Since LEF1 expression was not detected in any other lymphoma subtype, specificity was slightly higher in the Basel cohort (1.0) than in the Hammersmith cohort (0.93). This is most likely due to the different immunohistochemistry detection systems used. A more uniform and, thus, logically more sensitive expression pattern of LEF1 for the diagnosis of CLL was seen using an automated Leica immunostainer, and this has been previously documented. 7 On the other hand, the same clone of LEF1 antibody used on the Ventana system at Basel produced a more heterogeneous staining pattern and a lower sensitivity. This was true both in the current cohort of diagnostic cases and in a previously published TMA study on research cases. 9 Since the staining pattern did not differ between LN and decalcified BMTB samples in the two institutes, we conclude that decalcification did not have a significant influence on the staining quality. Further refinements to the LEF1 immunohistochemistry protocol currently used in Basel may improve the sensitivity on the Ventana system and need evaluation.
To conclude, we have shown that LEF1 is a valuable marker in the routine diagnostic hematopathology setting. It can be used in BMTB specimens, core needle biopsy specimens, whole LN excisions, or other tissue biopsy specimens. LEF1 workup is exceptionally helpful in small B-cell lymphomas with an equivocal immunophenotype or morphology. It is helpful in making a robust diagnosis of CLL. However, caution has to be exercised with the choice of primary antibody and of immunohistochemistry detection systems.
